Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).
Danielle Leão Cordeiro de FariasJoão PratsAlexandre Biasi CavalcantiRegis Goulart RosaFlávia Ribeiro MachadoOtávio BerwangerLuciano César Pontes de AzevedoRenato Deláscio LopesÁlvaro AvezumLeticia Kawano-DouradoLucas Petri DamianiSalomón Soriano Ordinola RojasCleyton Zanardo de OliveiraLuis Eduardo Coelho AndradeAlex Freire SandesMaria Carolina PintãoClaudio Galvão de Castro JúniorPhillip ScheinbergViviane Cordeiro VeigaPublished in: Revista Brasileira de terapia intensiva (2020)
The TOCIBRAS protocol was approved by local and central (national) ethical committees in Brazil following current national and international guidelines/directives. Each participating center had the study protocol approved by their institutional review boards before initiating protocol enrolment. The data derived from this trial will be published regardless of the results. If proven active, this strategy could alleviate the consequences of the inflammatory response in COVID-19 patients and improve their clinical outcomes.
Keyphrases
- study protocol
- randomized controlled trial
- inflammatory response
- sars cov
- quality improvement
- coronavirus disease
- open label
- clinical trial
- drug administration
- rheumatoid arthritis
- meta analyses
- lipopolysaccharide induced
- health insurance
- electronic health record
- early onset
- high intensity
- placebo controlled
- lps induced
- phase iii
- phase ii
- clinical practice
- double blind
- cross sectional
- toll like receptor
- decision making
- respiratory syndrome coronavirus
- rheumatoid arthritis patients